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Brief Clinical ReportsMitroflow pericardial aortic bioprosthesis in patients younger than
60 yearsCharles A. Yankah, MD, PhD, Berlin, GermanyTo date, the longest durability of pericardial aortic valves
was found in 49- and 70-year-old patients in series reported
by my colleagues and me,1,2 with explantation and death as
end points: 22 and 22.75 years, respectively.
However, the clear disadvantage of bioprostheses is the
propensity for failure in young patients as a result of struc-
tural valve deterioration (SVD), whereas pregnancy is not
a factor for accelerated SVD.3 There is a changing role of
pericardial bioprostheses in conjunction with mechanical
prostheses in the treatment of heart valve disease in young
patients because of morbidity associated with warfarin so-
dium (Coumadin) therapy and SVD.1-4 This effect was ex-
amined in the context of younger patients, under 60 years,
who received Mitroflow pericardial aortic valves (models
11 and 12; Sorin S.p.A., Saluggia, Italy) and have increased
exposure to the risk of SVD and replacement.FIGURE 1. Actuarial and actual freedom from structural valve deteriora-
tion (SVD) in patients under 60 years of age with Mitroflow pericardial
aortic valve prosthesis (model 12).CLINICAL SUMMARY
In early 2008,my colleagues and I2 reported our experience
with 1513 patients, 89 under 60 years, who received Mitro-
flow pericardial aortic valves (models 11 and 12). Implanta-
tion of model 11 started in 1986 and of model 12 in 1996.
The follow-up period for the evaluation was 1986 to 2007.
This brief communication comments on clinical experience
with 104 patients (48 women and 56 men) who were younger
than 60 years (median, 54.1  7.2; range, 22–60 years). Pre-
operative diagnoses were aortic valve incompetence (n¼ 22),
stenosis (n¼ 27), and combined lesions (n¼ 55). At a follow-
up of 477.8 patient-years (median 4.0 years), the reoperation
rate for SVD at 10 years was 7.7% at a linearized rate of 1.9%
per patient-year (1.8 vs 2.2% per patient-year for Mitroflow
models 11 and 12). Actuarial freedom from reoperation at
10 years was 72.5%  8.2%, and freedom from SVD for
models 11 and 12 was 82% and 84%, respectively
(P ¼ .0714; Figure 1). Actual risk of replacement for SVD
at 10 years for both models was 12%. Actuarial freedom
from thromboembolism at 10 years was 96.5%  2.1%.From Deutsches Herzzentrum Berlin, Germany.
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Durability of theMitroflowpericardial valve in patients un-
der 60 years at 18 years was 62% in comparison with 45% to
56% for porcine and allograft valves.2,4 In patients beyond 60
years the predicted probability of replacement of pericardial,
porcine, and allograft valves before death revealed no signif-
icant differences.4At rereplacement in our series, survival at 7
and 12 years in patients who reach the age of 60 to 69 years
was 100%, and it was 58% in patients older 70 years at 7
years. The data indicate that there is a survival advantage after
recovery of myocardial function in patients who undergo
a second valve operation.2 The Mitroflow pericardial aortic
valve has also demonstrated durability of up to 22.75 years
before explantation.2 Our data and reports of others throw
light on the elusive and unsettled question of implantation
of pericardial valves in patients under 60 years.1,2,4 In the light
of these encouraging results, the Mitroflow pericardial aortic
valve has demonstrated an important complementary role to
allograft and pulmonary autografts if it is implanted in appro-
priately selected patients.4,5References
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